21 – 30 of 88
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers : methodological update
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Impact of the COVID-19 pandemic on nuclear medicine departments in Europe
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
-
Mark
Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults
2020) In European Journal of Nuclear Medicine and Molecular Imaging(
- Contribution to journal › Article
-
Mark
Letter to editor
(
- Contribution to journal › Debate/Note/Editorial